Next Article in Journal
Effect of Le Fort I Maxillary Advancement and Clockwise Rotation on the Anteromedial Cheek Soft Tissue Change in Patients with Skeletal Class III Pattern and Midface Deficiency: A 3D Imaging-Based Prediction Study
Next Article in Special Issue
GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease
Previous Article in Journal
Clinical Factors Associated with Adherence to the Follow-Up Examination after Positive Fecal Occult Blood Test in National Colorectal Cancer Screening
Previous Article in Special Issue
Synaptic Pruning by Microglia in Epilepsy
Review

Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment

1
Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, 14200 Prague, Czech Republic
2
2nd Faculty of Medicine, Charles University, 15006 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 261; https://doi.org/10.3390/jcm9010261
Received: 9 December 2019 / Revised: 13 January 2020 / Accepted: 16 January 2020 / Published: 18 January 2020
(This article belongs to the Special Issue Glial Cells in Central Nervous System (CNS) Pathology and Repair)
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently by muscle atrophy. To date, numerous gene mutations have been linked to both sporadic and familial ALS, but the effort of many experimental groups to develop a suitable therapy has not, as of yet, proven successful. The original focus was on the degenerating motor neurons, when researchers tried to understand the pathological mechanisms that cause their slow death. However, it was soon discovered that ALS is a complicated and diverse pathology, where not only neurons, but also other cell types, play a crucial role via the so-called non-cell autonomous effect, which strongly deteriorates neuronal conditions. Subsequently, variable glia-based in vitro and in vivo models of ALS were established and used for brand-new experimental and clinical approaches. Such a shift towards glia soon bore its fruit in the form of several clinical studies, which more or less successfully tried to ward the unfavourable prognosis of ALS progression off. In this review, we aimed to summarize current knowledge regarding the involvement of each glial cell type in the progression of ALS, currently available treatments, and to provide an overview of diverse clinical trials covering pharmacological approaches, gene, and cell therapies. View Full-Text
Keywords: ALS; astrocytes; microglia; oligodendrocytes; NG2-glia; pericytes; clinical trials ALS; astrocytes; microglia; oligodendrocytes; NG2-glia; pericytes; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Filipi, T.; Hermanova, Z.; Tureckova, J.; Vanatko, O.; Anderova, M. Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020, 9, 261. https://doi.org/10.3390/jcm9010261

AMA Style

Filipi T, Hermanova Z, Tureckova J, Vanatko O, Anderova M. Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine. 2020; 9(1):261. https://doi.org/10.3390/jcm9010261

Chicago/Turabian Style

Filipi, Tereza, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko, and Miroslava Anderova. 2020. "Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment" Journal of Clinical Medicine 9, no. 1: 261. https://doi.org/10.3390/jcm9010261

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop